The 2023-2028 World Outlook for Pharma Contract Sales

The 2023-2028 World Outlook for Pharma Contract Sales

This study covers the world outlook for pharma contract sales across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using econometric models which project fundamental economic dynamics within each country and across countries, latent demand estimates are created. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved.

In this report we define the sales of pharma contract sales as including all commonly understood products and/or services falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include AbbVie, Actavis, Actelion Pharmaceuticals, Addison Whitney, Adheris Health, Akrikhin, Alexion, Allergan, Amgen, Andrx Pharmaceutials, Inc., Apple, Aralez Pharmaceuticals, Arbor Pharms Ireland, Arena Pharmaceuticals, Argon Global Healthcare Network, ARIAD, Arista, Ashfield Healthcare, AstraZeneca, BASF Schweiz, Bayer Healthcare, Berkshire Sterile Manufacturing (BSM), Biogaran, Blue Earth Diagnostics Limited., Boehringer Ingelheim, Bristol-Myers Squibb, Brusilow Enterprises, LLC, Campbell Alliance, Cegedim, Celesio, Celgene, Clovis Oncology, CMIC Ashfield, Create NYC, Daiichi Sankyo, Dendreon, Depomed, Eisai, Eli Lilly, Encore Health Resources, Endo Pharmaceuticals, Expansis, Galliard, Genentech, GlaxoSmithKline, Grey Healthcare Group, Group DCA, GSW, Haymarket Media, Health Kare Pharma International, In2Focus, INC Research, Ingelheim, inVentiv Health, Invida, IQVIA, J&J, J. Knipper & Company, Inc., Janssen Biotech, Kadrige, Knowledge Point360, Kos Pharmaceuticals, Marvecs, Medical Communications Group (MCG), MediMedia Health, Menarini, Merck, Merrimack, Microsoft, Millennium Pharmaceuticals, Mylan N.V., Navicor, Neurocrine Biosciences, NovaMed Pharmaceuticals, Novartis, Novella Clinical, Novo Nordisk, OnCall, Oracle, Otsuka/Bristol-Myers Squibb, PALIO, Parexel International, PDI, Pegasus, Pfizer, Pharmagistics, Pharmexx, Polpharma, Promius Pharma, Publicis Healthcare Communications Group (PHCG), Qforma, Quantia, Quintiles, Ramco Import Export, Regulus Therapeutics, Roche, Salesforce.com, Sanofi, Schering-Plough, Scientific Voice, Sermo, Servier, Sinclair IS Pharma, SmartAnalyst, Smithkline Beecham, Sofip (Société de Franchise pour l'Information Pharmaceutique), StayinFront, Symplmed Pharmaceuticals, Syneos Health, Synopia Rx, Taiho Oncology, Takeda, Tardis Medical, Temas, Tesaro, Teva Pharmaceutical Industries, The Medicines Company, United Therapeutics, Veeva, Vivus, and Zuellig Group. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022).